Keywords: AIDS treatment
Supportive therapy, to improve AIDS patients with progressive consumption as much as possible.
Second, immunomodulatory agents in the treatment:
(A) of the interleukin-2 (IL-2): to improve the body of HIV-infected cells, MHC-restricted cytotoxic effect, but also to improve the non-MHC-restricted natural killer cells (NK) and lymphokine-activated killer (LAK) cells activity.
(B) granulocyte colony stimulating factor (G-CSF) and granulocyte – macrophage colony-stimulating factor (GM-CSF): increased circulating neutrophils, improve the body’s resistance to infection.
(C) Spirit bacillin: to activate pituitary – adrenal system, adjust the body’s internal environment and function, enhance the body’s ability to adapt to changes in the external environment, to stimulate the body to produce humoral antibody, so that the increase in the total number of white blood cells and phagocytosis strengthen activation the body’s defense system to resist the invasion of pathogenic microorganisms and viruses.
(D) interferon (IFN): alpha-interferon (IFN-α), some patients may slightly increase the CD4 + T cells, 40% of patients with Kaposis sarcoma tumor subsided; ② of β-interferon (IFN-β): effect of intravenous administration is similar to the IFN-α, but subcutaneous, weak anti Kaposis sarcoma; ③ γ-interferon (IFN-γ) to improve monocytes – macrophage activity, anti-Toxoplasma conditions. infections may have a certain effect.
Third, antiviral agents:
(A) suppression of HIV with the host cell binding and penetration of the drug: soluble rsCD4 in conjunction with HIV occupy the CD4 binding site, so HIVgp120 can not be combined with the CD4 lymphocytes CD4T, not penetration infected CD4T lymphocytes.
Dose: rsCD4 clinical trials of 30mg / day, intramuscularly or intravenously, for 28 consecutive days.
Drugs: (b) the inhibition of HIV reverse transcriptase (RT), blocking HIV replication by inhibiting the reverse transcriptase. Better drugs are: azidothymidine, dideoxycytidine.